Mehr »
Dienstag, 07.12.2021 Börsentäglich über 12.000 News von 681 internationalen Medien



24 h / 7 T
7 Tage



24 h / 7 T
7 Tage














Erweiterte Suche

WKN: 578560 ISIN: DE0005785604 Ticker-Symbol: FRE 
17:35 Uhr
34,480 Euro
+3,08 %
PR Newswire
467 Leser
Artikel bewerten:

Fresenius Kabi at ESPEN Virtual Congress 2021: EuroPN Study will provide new clinical data on critical care nutrition

BAD HOMBURG, Germany, Oct. 11, 2021 /PRNewswire/ -- Real-world-data on the medical nutrition practice in Intensive Care Units (ICU) for critically ill patients is limited so far. To close this knowledge gap, Fresenius Kabi started EuroPN Study in 2019 in eleven European countries with around 100 participating hospitals[1]. At this year's congress of the European Society for Clinical Nutrition and Metabolism (ESPEN), experts discussed the study's set up and implementation in a virtual symposium[2] on September 10, 2021, chaired by Prof. Mette Berger, Switzerland, and Prof. Michael Hiesmayr, Austria.

(PRNewsfoto/Fresenius Kabi)

Does nutrition influence clinical outcome and prognosis?

The ESPEN guidelines for ICU patients[2] recommend a progressive increase in calorie and protein intake during the acute phase of critical illness, avoiding under and overfeeding. An important question in this context is, first to learn how medical nutrition therapy (MNT) is practiced across European ICU's and, secondly, if there is an association with MNT with clinical outcomes in critically ill patients in Europe.

Following this background, the primary objective of the EuroPN Study is to characterize the current use of clinical nutrition for critically ill adult patients in Europe and to assess nutritional balance, including calorie and protein balance. Secondary and tertiary study objectives were to investigate the association between nutrition and clinical outcomes, including time to weaning from invasive mechanical ventilation (IMV), overall survival time (OS), and mobility status.

The EuroPN: a large-scale European study

The EuroPN is a multinational, exploratory, non-interventional longitudinal cohort study which started in 2019 and has so far examined data from approximately 1200 critically ill patients who required intensive care for at least five consecutive days and maximum 20 days. There are around 100 hospitals in 11 European countries participating. These are: Czech Republic, France, Belgium, Germany, Spain, Hungary, Poland, Italy, the United Kingdom, Sweden and Austria. The study is one of the central projects of the "United for Clinical Nutrition" initiative, which Fresenius Kabi founded in 2014, to overcome hospital malnutrition around the world.

The study results are expected to be published within the next months. Further information for the media will follow.

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company's products and services are used to help care for critically and chronically ill patients. Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.

With its corporate philosophy of "caring for life," the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company reported sales of around €7.0 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group.

For more information, please visit

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release.

Management Board: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar Haszonits, Dr. Christian Hauer, Dr. Michael Schönhofen, Gerrit Steen
Chairman of the Supervisory Board: Stephan Sturm
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654

1. Hiesmayr M, Csomos A, Dams K, et al. Protocol for a prospective cohort study on the use of clinical nutrition and assessment of long-term clinical and functional outcomes in critically ill adult patients, Clinical Nutrition ESPEN.
2. Virtual Symposium by Fresenius Kabi at ESPEN virtual congress 2021: "New Clinical Data on Critical Care Nutrition (EuroPN Study) & Outlook on Future Research," 10 September 2021.

Logo -

Media contact:
Emese Kamp
PINK CARROTS Communications GmbH
Solmsstrasse 14
60486 Frankfurt am Main, Germany
+49 69 4272614-141

FRESENIUS-Aktie komplett kostenlos handeln - auf
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.